Home › Cardiovascular Disease › North Carolina › Greensboro
Cardiovascular Disease clinical trials in Greensboro, NC
5 studies for Cardiovascular Disease are looking for participants at sites in and around Greensboro (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RecruitingPhase 4
- Moses H Cone Memorial Hospital, Greensboro
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
RecruitingPhase 3
- Medication Management LLC, Greensboro
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RecruitingPhase 2
- Clinical Research Site, Greensboro
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RecruitingPhase 3
- Research Site, Greensboro
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RecruitingPhase 3
- Moses H Cone Memorial Hospital, Greensboro
- Medication Management LLC, Greensboro
- Triad Clinical Trials, LLC, Greensboro
Cardiovascular Disease trials in other cities
- Boston, MA37 studies
- New York City, NY33 studies
- Washington, DC28 studies
- Houston, TX24 studies
- Dallas, TX23 studies
- Atlanta, GA22 studies
- Cleveland, OH22 studies
- Chicago, IL21 studies
- Philadelphia, PA21 studies
- Pittsburgh, PA20 studies
- St. Louis, MO20 studies
- Nashville, TN18 studies
Other studies in Greensboro
- Overweight12 studies
- Obesity12 studies
- Type 2 Diabetes6 studies
- Heart Failure6 studies
- Breast Cancer5 studies
- HIV4 studies
- Stroke4 studies
- Interstitial Lung Diseases4 studies
- Heart Attack4 studies
- Lung Cancer3 studies
- Idiopathic Pulmonary Fibrosis3 studies
- Atherosclerosis3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.